Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:48 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 9,940 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Clear all
Completed No phase listed Observational

Eliminating Hepatitis C Virus

NCT03401697
View directory record Official record
Conditions
Hepatitis C, HIV, Type2 Diabetes
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
52 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 3 Interventional

A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3

NCT00000949
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

NCT00376090
View directory record Official record
Conditions
HIV Infections
Interventions
MVA-CMDR, Placebo
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults

NCT00853255
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Nov 3, 2026, 6:48 AM EST
Withdrawn Phase 2 Interventional

Garlic in Hyperlipidemia Caused by HAART

NCT00029250
View directory record Official record
Conditions
HIV Infections, Hypercholesterolemia, Hypertriglyceridemia, Hyperglycemia
Interventions
Garlic powder standardized to allicin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 3 Interventional

The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs

NCT00002391
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
3 Months to 12 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Fort Lauderdale, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)

NCT01227590
View directory record Official record
Conditions
Drug Interactions, Human Immunodeficiency Virus
Interventions
Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 1 Interventional

Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus

NCT00880789
View directory record Official record
Conditions
Cytomegalovirus Infection, Adenovirus Infection
Interventions
CMV/AdV specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 3 Interventional

The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00002389
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Berkeley, California • Los Angeles, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 6:48 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Video-based Counseling & Rapid HIV Testing for Teens

NCT00836550
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Video, in-person HIV pre-test counseling
Behavioral
Lead sponsor
North Bronx Healthcare Network
Other
Eligibility
15 Years to 21 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2009 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults

NCT00094718
View directory record Official record
Conditions
West Nile Fever Encephalitis
Interventions
WN/DEN4-3'delta30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Nov 3, 2026, 6:48 AM EST
Completed Not applicable Interventional

The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection

NCT00002290
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 2 Interventional Results available

Nitrite Supplementation in Long COVID Patients

NCT05618574
View directory record Official record
Conditions
Long COVID, Cardiorespiratory Fitness
Interventions
140 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK), 210 ml of nitrate-depleted placebo
Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

NCT03387150
View directory record Official record
Conditions
HIV Infections
Interventions
VRC07-523LS, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 2 Interventional Results available

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

NCT00920218
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine 1437173A, Placebo vaccine (saline)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • Duarte, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Nov 3, 2026, 6:48 AM EST
Terminated No phase listed Observational

A Study to Evaluate Rapid Throughput Screening for Human COVID-19 Infection

NCT04725097
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
2,821 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Shreveport, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Nov 3, 2026, 6:48 AM EST
Completed No phase listed Observational

Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection

NCT01771653
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Not listed
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years to 64 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Nov 3, 2026, 6:48 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Project Minority AIDS Prevention: Reaching Black and Hispanic MSM About PrEP and TasP Using Social Media

NCT03404531
View directory record Official record
Conditions
HIV Infections
Interventions
Social Media Messages Intervention Group, Website Only Group
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Nov 3, 2026, 6:48 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Engagement and Improving HIV Outcomes Via HealthMPowerment

NCT03678181
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases, Stigma, Social
Interventions
Information Resources, Social Support, HIV Testing
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years to 29 Years · Male only
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

NCT05854381
View directory record Official record
Conditions
HIV I Infection
Interventions
VIR-1388, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Nov 3, 2026, 6:48 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

NCT06920628
View directory record Official record
Conditions
Long COVID, Post Acute Sequelae of COVID-19
Interventions
11C-PS13
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 2 Interventional Results available

Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

NCT01526889
View directory record Official record
Conditions
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
Interventions
LFG316, Conventional Therapy
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
6
States / cities
Golden, Colorado • Marietta, Georgia • Cambridge, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

NCT02345226
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Nov 3, 2026, 6:48 AM EST
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

NCT01644643
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Shreveport, Louisiana • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Nov 3, 2026, 6:48 AM EST